Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation ແມ່ນສະພາບຜິວໜັງທີ່ມີລັກສະນະໂດຍການເພີ່ມເມັດສີໃນຜິວໜັງ ຫຼັງຈາກການອັກເສບຂອງຜິວໜັງ. Postinflammatory hyperpigmentation ສາມາດເກີດຈາກການຖືກແດດເປັນເວລາດົນ, ການອັກເສບ, ຫຼືການບາດເຈັບຂອງຜິວຫນັງອື່ນໆ, ລວມທັງສິ່ງທີ່ກ່ຽວຂ້ອງກັບສິວ. ຄົນທີ່ມີຜິວໜັງສີເຂັ້ມກວ່າປົກກະຕິມັກຈະເປັນຈຸດດ່າງດຳດ້ວຍການຖືກແສງແດດຫຼາຍ.
☆ ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
References
Postinflammatory hyperpigmentation (PIH) ເປັນບັນຫາຜິວຫນັງທີ່ເກີດຂື້ນເລື້ອຍໆຫຼັງຈາກຜິວຫນັງອັກເສບຫຼືການບາດເຈັບ. ມັນມີແນວໂນ້ມທີ່ຈະຢູ່ໄດ້ດົນ ແລະຮ້າຍແຮງຂຶ້ນໃນຄົນທີ່ມີຜິວໜັງສີດຳ (Fitzpatrick skin types III–VI) . ເຖິງແມ່ນວ່າມັນມັກຈະດີຂຶ້ນດ້ວຍຕົວມັນເອງ, ນີ້ສາມາດໃຊ້ເວລາໄລຍະຫນຶ່ງ, ດັ່ງນັ້ນການປິ່ນປົວແມ່ນມັກຈະເປັນເວລາດົນນານ. ການສົມທົບການປິ່ນປົວທີ່ແຕກຕ່າງກັນເຮັດວຽກທີ່ດີທີ່ສຸດ.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ເປັນຜົນມາຈາກການອັກເສບຂອງຜິວໜັງ. ມັນມີແນວໂນ້ມທີ່ຈະສົ່ງຜົນກະທົບຕໍ່ບຸກຄົນທີ່ມີຜິວ ໜັງ ເຂັ້ມກວ່າແລະເລື້ອຍໆ. ການສຶກສາສະແດງໃຫ້ເຫັນວ່າບັນຫາເຊັ່ນ postinflammatory hyperpigmentation ແມ່ນ ໜຶ່ງ ໃນເຫດຜົນຕົ້ນຕໍທີ່ເຮັດໃຫ້ຄົນທີ່ມີຜິວ ໜັງ ມືດສະແຫວງຫາການດູແລຮັກສາຜິວ ໜັງ. ການປິ່ນປົວເບື້ອງຕົ້ນແມ່ນສໍາຄັນສໍາລັບການແກ້ໄຂ postinflammatory hyperpigmentation ແລະປົກກະຕິແລ້ວເລີ່ມຕົ້ນດ້ວຍການຄຸ້ມຄອງສະພາບອັກເສບເບື້ອງຕົ້ນ. ເສັ້ນທໍາອິດຂອງການປິ່ນປົວໂດຍທົ່ວໄປແມ່ນກ່ຽວຂ້ອງກັບການນໍາໃຊ້ຕົວແທນທີ່ເຮັດໃຫ້ມີແສງຜິວຫນັງພ້ອມກັບ sunscreen ສໍາລັບການປົກປ້ອງ. ຕົວແທນເຫຼົ່ານີ້, ເຊັ່ນ hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , ສາມາດຫຼຸດຜ່ອນເມັດສີຫຼາຍເກີນໄປໄດ້ຢ່າງມີປະສິດທິພາບ. ນອກຈາກນັ້ນ, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy ຍັງຖືກໃຊ້ເປັນສານຂັດສີ, ດ້ວຍການປິ່ນປົວໃໝ່ໆທີ່ປະກົດອອກມາ. ໃນຂະນະທີ່ການປິ່ນປົວຕາມປົກກະຕິແມ່ນມີປະສິດທິຜົນສໍາລັບການ hyperpigmentation ລະດັບຫນ້າດິນ, ຂັ້ນຕອນ (laser, chemical peel) ອາດຈະເປັນສິ່ງຈໍາເປັນສໍາລັບກໍລະນີທີ່ແຂງກະດ້າງ. ມັນເປັນສິ່ງສໍາຄັນທີ່ຈະໃຊ້ຄວາມລະມັດລະວັງກັບການປິ່ນປົວເຫຼົ່ານີ້ເພື່ອຫຼີກເວັ້ນການລະຄາຍເຄືອງແລະການຮ້າຍແຮງຂຶ້ນຂອງ postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
